Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oprozomib with Sorafenib in Advanced Hepatocellular Carcinoma
NCT02227914Phase 2Withdrawn
- Sponsor
- Amgen
- Start
- Dec 2014
- Primary completion
- Mar 2015
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oprozomib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Amgen. Primary endpoints: Maximum Tolerated Dose at 16 months and Time To Progression at 16 months. Planned start Dec 2014; status: withdrawn.
02
Drugs
oprozomib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02227914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227914.